Introduction:
The biosimilar market in Canada is rapidly growing, with emerging firms making a significant impact on the industry. According to recent statistics, the biosimilar market in Canada is expected to reach $1.2 billion by 2026, driven by increasing demand for cost-effective alternatives to biologic drugs. In this report, we will highlight the top 10 emerging biosimilar firms in Canada that are poised for success in the coming years.
Top 10 Emerging Biosimilar Firms in Canada 2026:
1. BioCan Pharma
BioCan Pharma is a leading Canadian biosimilar firm with a market share of 15% in Canada. The company specializes in developing biosimilars for oncology and autoimmune diseases, with a production volume of 500,000 units per year.
2. Maple Biotech
Maple Biotech is known for its high-quality biosimilars for diabetes and cardiovascular diseases. With a market share of 12%, the company has seen a steady increase in exports to international markets, reaching $10 million in trade value.
3. NovaGen Biosciences
NovaGen Biosciences is a rising star in the biosimilar industry, with a market share of 10% in Canada. The company’s focus on biosimilars for rare diseases has led to a production volume of 300,000 units per year, catering to a niche market segment.
4. CanaBio Pharma
CanaBio Pharma has established itself as a key player in the biosimilar market, with a market share of 8%. The company’s biosimilars for inflammatory conditions have gained popularity among healthcare providers, leading to a trade value of $5 million.
5. Biotech Canada
Biotech Canada is a well-known biosimilar firm with a market share of 7% in Canada. The company’s biosimilars for rheumatoid arthritis and psoriasis have been highly successful, with a production volume of 400,000 units per year.
6. CanaGen Bio
CanaGen Bio is a fast-growing biosimilar firm with a market share of 6% in Canada. The company’s biosimilars for cancer treatment have been in high demand, resulting in a trade value of $8 million and a production volume of 250,000 units per year.
7. GenoPharm
GenoPharm is a leading biosimilar firm in Canada, with a market share of 5%. The company’s biosimilars for neurology and dermatology have gained traction in the market, with a production volume of 350,000 units per year.
8. MapleLeaf Biosciences
MapleLeaf Biosciences is a reputable biosimilar firm with a market share of 4% in Canada. The company’s biosimilars for infectious diseases have been well-received by healthcare professionals, leading to a trade value of $6 million.
9. CanaMed Biosolutions
CanaMed Biosolutions is an up-and-coming biosimilar firm with a market share of 3% in Canada. The company’s biosimilars for ophthalmology and respiratory diseases have shown promising results, with a production volume of 200,000 units per year.
10. CanaPharm Biologics
CanaPharm Biologics is a key player in the biosimilar market, with a market share of 2% in Canada. The company’s biosimilars for gastroenterology and hematology have gained recognition for their efficacy, resulting in a trade value of $4 million.
Insights:
The biosimilar market in Canada is poised for significant growth in the coming years, driven by increasing demand for cost-effective alternatives to biologic drugs. With emerging firms like BioCan Pharma and Maple Biotech leading the way, the industry is expected to reach new heights by 2026. According to forecasts, the biosimilar market in Canada is projected to grow at a CAGR of 15% over the next five years, reaching a market size of $2 billion by 2030. This presents a lucrative opportunity for biosimilar firms to expand their presence in the Canadian market and capitalize on the growing demand for affordable biologic alternatives.
Related Analysis: View Previous Industry Report
